Diatide aims to commercialise lung imaging agent:
This article was originally published in Clinica
Diatide is licensing technology from Merck on a non-exclusive basis to assist in commercialising its pulmonary embolism imaging agent, P748. The product is in Phase II trials. Londonderry, New Hampshire-based Diatide has one FDA-approved product, AcuTect, for scintigraphic imaging of acute venous thrombosis in the lower extremities and has a pipeline of products for specific disease states, based on high affinity radio-labelled peptides.
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.